Company Profile
Tenax Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- TENX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.75 USD (-1.69%)
Close
Last updated: August 21, 2026
290M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, TENX closed down 1.69% at $1.75. No new same-company headline was identified in the current news window.
Company overview
Phase 3 Cardiopulmonary Developer
Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary disease. Its strategy is centered on levosimendan, a K-ATP channel activator and calcium sensitizer being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF.
Lead Program: TNX-103
TNX-103 is the oral formulation of levosimendan and is being evaluated in two pivotal Phase 3 trials, LEVEL and LEVEL-2. The program is designed for a disease setting with no approved therapy, giving Tenax a focused development path in a high-need cardiopulmonary population.
Clinical Rationale
Levosimendan has prior global experience as an intravenous therapy for acutely decompensated heart failure outside the U.S. and Canada. Tenax's Phase 2 HELP trial and open-label extension supported the potential for IV TNX-101 and oral TNX-103 to improve exercise capacity, quality of life, and other clinical assessments in PH-HFpEF.
Strategic Position
Tenax is best understood as a single-asset, late-stage cardiopulmonary company. Its value is tightly linked to whether oral levosimendan can establish clinically meaningful benefit in PH-HFpEF and support a regulatory path in a market with no approved product.
Future catalysts
- Topline data from the Phase 3 LEVEL trial expected in August 2026.
- LEVEL results presentation planned for ESC Congress 2026.
- Expected LEVEL-2 enrollment completion by the end of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tenax Therapeutics, Inc. (TENX)?
Tenax Therapeutics, Inc. (TENX) most recently closed at 1.75 USD, a -1.69% move versus the previous session.
What is the market cap of Tenax Therapeutics, Inc. (TENX)?
Tenax Therapeutics, Inc. currently has a market capitalization of 290M USD on BioPharmSignal.
What does Tenax Therapeutics, Inc. do?
Phase 3 Cardiopulmonary Developer Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary disease. Its strategy is centered on levosimendan, a K-ATP channel activator and calcium sensitizer being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. Lead...
On which exchange is TENX stock listed?
Tenax Therapeutics, Inc. (TENX) is associated with NASDAQ, United States, Biopharma.
What is TNX-103?
Lead Program: TNX-103 TNX-103 is the oral formulation of levosimendan and is being evaluated in two pivotal Phase 3 trials, LEVEL and LEVEL-2.
Which conditions is Tenax Therapeutics, Inc. targeting with TNX-103?
Phase 3 Cardiopulmonary Developer Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary disease. Its strategy is centered on levosimendan, a K-ATP channel activator and calcium sensitizer being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. Lead...
How does Tenax Therapeutics, Inc. describe recent progress with TNX-103?
Topline data from the Phase 3 LEVEL trial expected in August 2026. LEVEL results presentation planned for ESC Congress 2026. Expected LEVEL-2 enrollment completion by the end of 2027.
What is LEVEL-2?
Lead Program: TNX-103 TNX-103 is the oral formulation of levosimendan and is being evaluated in two pivotal Phase 3 trials, LEVEL and LEVEL-2.